Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: patiromer Clear all
Terminated Phase 2 Interventional Results available

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

NCT02033317
View directory record Official record
Conditions
Hyperkalemia
Interventions
patiromer
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 6, 2026, 7:50 AM EDT
Recruiting Phase 2 Interventional

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

NCT05766839
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
0 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 6, 2026, 7:50 AM EDT
Completed No phase listed Observational

High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure

NCT02823626
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Spironolactone and patiromer
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 4 Interventional Results available

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

NCT02933450
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Patiromer 25.2 g
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 6, 2026, 7:50 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease

NCT05050110
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Fruits and Vegetable increase
Other
Lead sponsor
Nand Wadhwa
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Port Jefferson Station, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 6, 2026, 7:50 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Potassium Binders in the ER

NCT04585542
View directory record Official record
Conditions
Acute Hyperkalemia, Oral Potassium Binders
Interventions
Polyethylene Glycol 3350, Sodium Polystyrene Sulfonate Oral Suspension [SPS], Patiromer, Sodium zirconium cyclosilicate
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 6, 2026, 7:50 AM EDT
Completed No phase listed Observational

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

NCT04566653
View directory record Official record
Conditions
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
Interventions
Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water, Veltassa® 8,4 g/80mL water, Sodium Polystyrene Sulphonate 15g/60 mL water
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Temple Terrace, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

NCT01810939
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Hyperkalemia (HK)
Interventions
Patiromer, Placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
14
States / cities
Azusa, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Patiromer in Heart Failure Patients

NCT00868439
View directory record Official record
Conditions
Hyperkalemia, Heart Failure
Interventions
patiromer, placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Miami, Florida • Port Charlotte, Florida • Peoria, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 6, 2026, 7:50 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

NCT03087058
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Palo Alto, California • Kansas City, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 6, 2026, 7:50 AM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis: The TwoPlus Trial

NCT05828823
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Hemodialysis twice weekly, Hemodialysis thrice weekly
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 7:50 AM EDT
Terminated Phase 4 Interventional

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

NCT04443608
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer Powder for Oral Suspension [Veltassa], Placebo
Drug
Lead sponsor
Comprehensive Research Associates
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 6, 2026, 7:50 AM EDT
Terminated Phase 4 Interventional Results available

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On

NCT03597035
View directory record Official record
Conditions
Type2 Diabetes, Hyperkalemia
Interventions
Spironolactone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

NCT03740048
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Hemodialysis, Patiromer Oral Product
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 4 Interventional Results available

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

NCT03781089
View directory record Official record
Conditions
Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer Oral Powder Product
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 4 Interventional

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

NCT03229265
View directory record Official record
Conditions
Hyperkalemia, Kidney Transplant
Interventions
Patiromer
Drug
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

NCT03071263
View directory record Official record
Conditions
Hyperkalemia, Resistant Hypertension
Interventions
Patiromer, Placebo, Spironolactone
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Hollywood, Florida • Miami Lakes, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 4 Interventional Results available

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

NCT03183778
View directory record Official record
Conditions
Chronic Kidney Diseases, Hyperkalemia
Interventions
Patiromer, Research Diet Menu
Drug · Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 4 Interventional Results available

Patiromer With or Without Food for the Treatment of Hyperkalemia

NCT02694744
View directory record Official record
Conditions
Hyperkalemia
Interventions
patiromer
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
29
States / cities
Fountain Valley, California • Huntington Beach, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 6, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 6, 2026, 7:50 AM EDT